Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:


Last Updated: October 1, 2022

Details for Patent: 8,945,620

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,945,620 protect, and when does it expire?

Patent 8,945,620 protects LYRICA CR and is included in one NDA.

Protection for LYRICA CR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-seven patent family members in thirty-three countries.

Summary for Patent: 8,945,620
Title:Solid pharmaceutical compositions containing pregabalin
Abstract: A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.
Inventor(s): Bockbrader; Howard N. (Ann Arbor, MI), Cho; Yun Hyung (Lexington, MA), Diaz Santiago; Steven (Martinsville, NJ), Mahjour; Majid (Schwenksville, PA), Reynolds; Thomas Daniel (Morgantown, WV), Shao; Pushpa Ganapathi (San Diego, CA), Shao; Zezhi Jesse (San Diego, CA), Wan; Jiansheng (Short Hills, NJ)
Assignee: Warner-Lambert Company LLC (New York, NY)
Application Number:14/181,785
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound; Delivery;

Drugs Protected by US Patent 8,945,620

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Upjohn LYRICA CR pregabalin TABLET, EXTENDED RELEASE;ORAL 209501-001 Oct 11, 2017 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Upjohn LYRICA CR pregabalin TABLET, EXTENDED RELEASE;ORAL 209501-002 Oct 11, 2017 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Upjohn LYRICA CR pregabalin TABLET, EXTENDED RELEASE;ORAL 209501-003 Oct 11, 2017 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,945,620

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 058175 See Plans and Pricing
Australia 2006310217 See Plans and Pricing
Brazil PI0618211 See Plans and Pricing
Canada 2628200 See Plans and Pricing
China 101330907 See Plans and Pricing
Costa Rica 9950 See Plans and Pricing
Cyprus 1115009 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.